Question 1

What are the most cited papers from Gilead Sciences (Canada)?

Accepted Answer

The most cited paper from Gilead Sciences (Canada) is "Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults" (Patricia Barditch‐Crovo, Steven G. Deeks, Ann Collier et al., 2001), with 335 citations. Next come "Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9- R -(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA" (325) and "Management of adverse events associated with idelalisib treatment: expert panel opinion" (312).

Question 2

Which research topics does Gilead Sciences (Canada) publish most on?

Accepted Answer

By volume in 2022-now: HIV/AIDS drug development and treatment, CAR-T cell therapy research, HIV-related health complications and treatments and Traffic Prediction and Management Techniques.

Question 3

Which keywords describe research at Gilead Sciences (Canada)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Antiretroviral Therapy, Epidemiology, HIV Infection, Inflammation, Lymphoma, Immune Response, Immunotherapy and Cancer Immunotherapy.

Question 4

Which fields of science does Gilead Sciences (Canada) work in?

Accepted Answer

In all years, 51% of research at Gilead Sciences (Canada) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (48%), Biochemistry, Genetics and Molecular Biology (15%), Immunology and Microbiology (7%). It does 1.8× the world's share of Health Sciences.

Question 5

Is Gilead Sciences (Canada)'s research output growing?

Accepted Answer

Output in 2022-2025 was 63% higher than in 2018-2021.